This multitarget profile is particularly relevant in triple-positive breast cancer, where PR, ER-α, and HER2 converge on the PI3K/AKT/mTOR (PAM) pathway, a central axis of tumor growth and endocrine resistance. Here, ERBB2 is linked to neoplasm.